Is a recently identified neurological condition primarily linked to refractory frontal lobe epilepsy, especially in pediatric patients. Histologically characterized by clusters of increased oligodendroglial cell density, blurred gray-white matter boundaries, and heterotopic neurons within the white matter, MOGHE presents distinct magnetic resonance imaging (MRI) features, such as increased T2/FLAIR signal intensity. These imaging characteristics are crucial for the diagnosis and management of this condition, which frequently results in diverse seizure types and cognitive decline that resist conventional treatments.[1][2][3][4].Notably, MOGHE is particularly significant due to its association with difficult-to-treat epilepsy and potential for surgical intervention. However, studies indicate that patien- ts with MOGHE often experience unfavorable outcomes concerning seizure control

following surgical resection, emphasizing the need for a deeper understanding of its MRI characteristics and underlying pathology.[1][3][4]. Additionally, recent research has highlighted two MRI subtypes that correlate with age and histological findings, suggesting an age-related progression of the condition.[5][6].

The etiology of MOGHE appears to involve abnormal oligodendroglial proliferation and neuronal migration, with emerging genetic studies identifying somatic variants in the SLC35A2 gene among affected individuals. These findings enhance the under- standing of the condition's pathophysiology, potentially informing future therapeutic approaches.[2][6][7]. As advancements in imaging and genetic research continue, MOGHE remains a focal point for ongoing investigation into effective diagnosis and treatment strategies for pediatric epilepsy related to cortical malformations.[2][7].

Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE) is a recently recognized entity primarily associated with refrac- tory frontal lobe epilepsy, particularly in pediatric populations. Histopathologically, MOGHE is characterized by clusters of increased oligodendroglial cell density, blurred gray-white matter boundaries, and heterotopic neurons within the white matter[1][2][3]. These features typically manifest on MRI as increased T2/FLAIR signal intensity, highlighting the structural abnormalities in the frontal lobe[1][4]. The condition often presents in children or young adults and is marked by a spectrum of seizure types, including focal, atonic, and tonic seizures, which are frequently resistant to anti-seizure medications[2][3]. Cognitive decline is also common among affected individuals, further complicating their neurological status[3]. The patho- genesis of MOGHE appears to involve abnormal oligodendroglial proliferation and neuronal migration, leading to significant alterations in cortical architecture[2][4][3]. Surgical resection of the affected brain tissue is currently the main treatment for patients with MOGHE who do not respond to pharmacological interventions. How- ever, studies indicate that the presence of MOGHE is associated with an unfavorable outcome in terms of seizure control post-surgery[1][4][3]. Understanding the MRI characteristics and underlying pathology of MOGHE is crucial for improving diagnosis and management of this challenging condition.

Magnetic Resonance Imaging (MRI) plays a crucial role in the assessment of patients with mild malformation of cortical development with oligodendroglial hyperplasia and epilepsy (MOGHE). Recent studies have identified distinct MR subtypes that correlate with age and histological findings, providing insights into the condition's pathophysiology.

Subtypes of MR Findings

Two primary MRI subtypes have been characterized in MOGHE patients. Subtype I is marked by increased laminar T2 and fluid-attenuated inversion recovery (FLAIR) signals at the corticomedullary junction, typically observed in younger patients be- tween the ages of 1.5 and 5.1 years (median age: 2.6 years). Conversely, Subtype II exhibits reduced corticomedullary differentiation due to increased signal intensity in

adjacent white matter, predominantly seen in older children aged 3.4 to 20.7 years (median age: 14.1 years)[5][6].

Age-Related Changes

The transition from Subtype I to Subtype II appears to be age-related, likely reflecting maturational processes. In a notable case, a patient exhibited Subtype I character- istics at the age of 2.7 years, which evolved into Subtype II by 16 years of age. Histological examinations revealed that areas of reduced myelin density seen in Subtype I may dissipate as the brain matures, thereby paralleling the observed MR changes[6][1].

Histopathological Correlations

Histological analysis has shown that the typical MR findings in MOGHE correlate with distinct pathological features. In patients with Subtype I, areas of hypomyelination were noted, suggesting a link between MRI hyperintensities and underlying oligoden- droglial proliferation. This connection underscores the importance of integrating MR characteristics with histological findings to enhance understanding and management of MOGHE[6][8].

Mild malformation of cortical development with oligodendroglial hyperplasia (MMCD-OH) can have significant clinical implications, particularly in relation to diagnosis and treatment. Accurate diagnosis often hinges on a combination of clinical symptoms, imaging studies such as MRI, and laboratory tests to rule out other conditions. MRI plays a crucial role in identifying characteristic features of the disorder, which can assist in distinguishing it from similar demyelinating diseases like MOG antibody disease and neuromyelitis optica (NMO) spectrum disorder[8].

The timing of intervention is critical for optimizing patient outcomes. Studies suggest that early therapy can lead to improved recovery outcomes, especially in children, who may demonstrate greater neuroplasticity compared to adults[8]. The importance of early treatment is underscored by the fact that symptoms can exacerbate due

to stressors, which may mimic or worsen existing conditions without indicating new lesions on MRI[8].Management typically involves a tailored approach that may include immunosup- pressive or immunomodulatory therapies aimed at preventing relapses and further disability. These therapies are most effective when aligned with active symptoms and appropriate MRI findings[8]. Furthermore, clinicians must consider the potential for false positives in antibody testing, particularly in the context of recent viral infections like COVID-19, making it essential to correlate serological findings with clinical symptoms and MRI results[8].

Research and Advances

The intersection of genetic, imaging, and clinical research continues to shape the understanding of MOGHE. Future studies are expected to further delineate the molecular mechanisms at play and explore novel therapeutic avenues aimed at improving patient outcomes in epilepsy associated with cortical malformations.[2]

Recent studies have illuminated the genetic landscape associated with mild mal- formation of cortical development with oligodendroglial hyperplasia (MOGHE). A targeted gene panel sequencing of 20 formalin-fixed, paraffin-embedded (FFPE) MOGHE tissues revealed somatic variants in the SLC35A2 gene in 9 out of 20 patients, indicating a significant genetic burden of 45%.[2] The identified variants in- cluded six loss-of-function mutations, which were classified as pathogenic, and three missense variants that were deemed likely pathogenic based on American College of Medical Genetics and Genomics (ACMG) guidelines.[2] Notably, these variants were absent from the gnomAD database, underscoring their potential relevance in MOGHE pathology.[2]

Somatic Mosaicism and Epilepsy

The role of somatic mosaicism has emerged as a crucial factor in the etiology of MOGHE and other forms of epilepsy. Mosaic variants in the SLC35A2 gene have been implicated in various forms of non-lesional focal epilepsies and focal cortical dysplasia (FCD) types 1 and 2.[2] This association highlights the importance of understanding the mechanisms underlying somatic mutations and their contribution to developmental brain disorders.[2]

Advances in Imaging Techniques

In addition to genetic findings, advancements in imaging techniques are improving the diagnosis and characterization of MOGHE. Magnetic resonance imaging (MRI) plays a pivotal role in distinguishing MOGHE from other demyelinating conditions, such as multiple sclerosis (MS). MRI findings in MOGHE may exhibit unique char- acteristics, which can aid clinicians in accurate diagnosis and treatment planning.[7] Ongoing research aims to elucidate these imaging features further, potentially pro- viding insights into the underlying pathology of MOGHE and informing therapeutic strategies.[7]

Research in this field has been supported by various funding bodies, includingthe European Research Council and the National Research Foundation of Korea, ensuring rigorous scientific inquiry into MOGHE and related disorders.[2] Ethical considerations have been paramount, with studies receiving approval from multiple institutional review boards, underscoring the commitment to responsible research practices in this sensitive area of study.[2]